Group 1 - The call includes forward-looking statements reflecting the company's perspective as of November 10, 2025 [1] - The company does not commit to updating or revising forward-looking statements unless legally required [1] Group 2 - Key personnel present include the Founder and CEO, Chief Medical Officer, and Chief Commercial Officer, along with leading experts in hyperinsulinism [2] - Dr. Mansa Krishnamurthy and Dr. Azeez Farooki are recognized experts in the field, contributing to the discussion on congenital hyperinsulinism and tumor-related endocrine complications [2]

Summary of Rezolute Investor Event Conference Call Company Overview - **Company**: Rezolute - **Focus**: Rare disease company targeting severe hypoglycemia associated with hyperinsulinism - **Key Product**: IrsodaTug (also known as ERSO), an antibody in late-stage clinical trials aimed at treating all forms of hyperinsulinism [4][5][6] Industry Context - **Hyperinsulinism**: A condition characterized by excessive insulin leading to persistent hypoglycemia, particularly in infants and children - **Congenital Hyperinsulinism**: A chronic disease affecting 1 in 22,000 patients, with severe cases presenting within the first month of life [9][10] - **Tumor Hyperinsulinism**: Caused by insulinomas or non-islet cell tumors, leading to similar hypoglycemic symptoms [17][18] Key Points from the Call Clinical Development - **IrsodaTug Mechanism**: Modulates insulin receptor binding and signaling, aiming to normalize glucose levels regardless of the underlying cause of hyperinsulinism [5] - **Clinical Trials**: - Phase III study for congenital hyperinsulinism is ongoing, with top-line results expected in December 2025 [6][34] - A small single-arm open-label study for tumor hyperinsulinism is planned, focusing on patients requiring continuous glucose infusion [39] Efficacy and Safety - **Previous Studies**: Phase IIB study showed significant correction in hypoglycemic events [6] - **Patient Impact**: Real-world evidence indicates profound improvements in quality of life for patients treated under expanded access programs [6] Unmet Medical Need - **Current Treatments**: Existing therapies like diazoxide are ineffective in about 60% of patients with potassium ATP channel mutations and have significant side effects [12][13] - **Quality of Life**: Patients face severe risks including seizures and neurological damage due to hypoglycemia, highlighting the need for better treatment options [11][16] Market Opportunity - **Congenital Hyperinsulinism**: Approximately 165 new cases annually in the U.S., with 90% of patients under 18 years old [45][46] - **Tumor Hyperinsulinism**: Estimated 3,000 new cases of malignant insulinoma annually, with a significant portion being refractory to current treatments [54][55] - **Addressable Patient Population**: Initial estimates suggest around 1,500 pediatric patients for congenital HI and 750 for malignant insulinoma at launch [56][60] Commercial Strategy - **Targeted Approach**: Focus on 90 major children's hospitals and a small sales team to engage pediatric endocrinologists [46][50] - **Patient Engagement**: Launch of a disease state website to support families affected by congenital HI [51] - **Payer Research**: Positive reception from payers regarding IrsodaTug, with expectations for favorable coverage due to its differentiated efficacy [53] Regulatory Milestones - **Breakthrough Designation**: Received from the FDA for both congenital and tumor hyperinsulinism indications, streamlining the development process [41][42] Future Outlook - **Enrollment and Results**: Anticipation of top-line data for the congenital HI study in December 2025 and completion of enrollment for the tumor HI study by 2026 [39][40] Conclusion - Rezolute is positioned to address significant unmet needs in the treatment of hyperinsulinism through IrsodaTug, with promising clinical data and a focused commercial strategy aimed at pediatric patients and specialized treatment centers [41][63]